ACDIS CCDS-O Exam With Confidence Using Practice Dumps

Symbicort is an inhaled combination medication containing an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA). In outpatient chart review, this medication class is most strongly associated with chronic airway inflammatory diseases requiring controller therapy—especiallypersistent asthma(and also maintenance therapy for COPD, though COPD is not an option here). For CDI purposes, medication-to-diagnosis linkage can act as a clinical indicator supporting clarification when the visit note lists respiratory symptoms but does not clearly document the chronic condition being treated or its acuity/status. Symbicort is not used to treat musculoskeletal degenerative disease (osteoarthritis), peripheral nerve pain from diabetes (diabetic neuropathy), or cardiac pump failure (congestive heart failure). When Symbicort appears on the active med list, outpatient CDI commonly checks that the provider’s documentation appropriately reflects asthma classification (intermittent vs persistent), current control, exacerbation status if applicable, and that the condition is being monitored/assessed/treated during the encounter to support reportability and accurate coding.

In ambulatory CDI chart review, clinical indicators should align with assessment and management captured in the note (problem relevance and MEAT-style support: monitor, evaluate, assess/address, treat). This visit has two strong indicators that warrant medication evaluation. First, dyspnea plus a rapid 10-lb weight increase over two weeks is a classic signal of possible fluid overload in a patient with heart failure, making a loop diuretic such as Lasix clinically relevant to assess (effectiveness, adherence, dose changes, exacerbation risk, and whether HF is stable vs decompensated). Second, the A1c has worsened significantly (9.2 from 7.2), indicating inadequate glycemic control that should prompt review and adjustment of diabetes therapy; insulin such as NovoLog is directly tied to diabetes treatment escalation or optimization. The other medication pairs do not logically match the documented problems and indicators (e.g., appetite stimulant/anemia therapy, immunosuppressant, antidepressant/antihistamine). Therefore, NovoLog and Lasix best reflect what should be evaluated and addressed

In the outpatient setting, diagnoses documented as uncertain (e.g., “possible,” “probable,” “suspected,” “rule out”) are generally not coded as confirmed conditions; instead, coding is based on confirmed diagnoses or, when not confirmed, the presenting signs/symptoms. Here, the provider documented only “possible Zika,” which is not a confirmed diagnosis for outpatient reporting. Even though the CDI specialist sees a positive serology result, lab data alone does not replace provider diagnostic confirmation in the assessment/plan. The appropriate next step is to query the provider to confirm whether Zika is the established diagnosis based on the positive test (and whether it is clinically addressed during the encounter). If confirmed, Zika can be coded appropriately and sequenced based on the reason for the visit; if not confirmed or still under evaluation, the symptom (fever) remains first-listed. Option B is incorrect because coders do not “code the result” of a serology test as a diagnosis; they code the condition the test supports once clinically confirmed.